我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
' P) e' C7 _! ~% I0 R2 B& R# G+ Author Affiliations
2 J, z7 y" d' d& M# X" n
; v& C2 Z6 h( N' L( c' c6 e1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& C) [* h6 O6 ~# D/ a2 z/ j' G/ B- m9 Q3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
' k7 ~% D, T2 n0 `$ e7 V5 @" \7Kinki University School of Medicine, Osaka 589-8511, Japan
! R; s+ D$ K- c6 z& H8Izumi Municipal Hospital, Osaka 594-0071, Japan
7 U( k% N) |5 y2 Q8 @6 ~' G4 q9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
* _/ `0 {! A% r0 E' W* ~AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.

, U, K+ g; ?: p3 t8 V+ N, I6 L6 m0 {

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
' t$ Z2 B8 x1 y6 e$ e1 E( D
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
/ C$ N! n+ S' ~* Z
# n; [2 {# m( U' N# o/ H+ e  A$ PAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  

# O9 Q- R: T* f# \' UPublished online on: Thursday, December 1, 2011
* s/ R! ]* [3 U
Doi: 10.3892/ol.2011.507

Pages: 405-410
* f0 i9 ]. W$ E# B  C  n. B
Abstract:
6 I  n# W; F' ~6 ]; d, T" ES-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
6 l3 p- B/ d9 t% g! RF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
: t  ?6 F, }6 S* Z) F+ Author Affiliations
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
2Department of Thoracic Surgery, Kyoto University, Kyoto
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
Received September 3, 2010.
  d$ H! E, a  G! ~: X2 HRevision received November 11, 2010.
Accepted November 17, 2010.
8 y% o9 u3 G& R$ D1 d6 @2 YAbstract
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
4 a9 n. }& K! N. J* o% uPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
# @1 k) D) q4 N5 C$ M& HResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
' }4 o& x' Y- q! i4 k

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
( l- S7 d# q7 m& a" J7 Y1 u! U今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
: b* j. G/ q7 Y1 d# z) ehttp://clinicaltrials.gov/ct2/show/NCT01523587

5 _6 X% i* r! y, T) G# y4 @: K: _) VBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
9 z- }. L& c# j) Q3 ^, y' p5 Y3 Shttp://clinicaltrials.gov/ct2/show/NCT01156545

, g5 {6 y1 F0 Q9 ^; @从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
. V0 g3 b, y. F0 p至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

                               
登录/注册后可看大图

! ?: J' D& u9 {7 |. S; M! v从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
! o, w: P8 G" O- j. b至今为止，未出 ...

没有副作用是第一追求，效果显著是第二追求。
6 i8 ^. E! w# m% F* P不错。